首页 > 市场调查报告书 > 医疗设备

药物递输设备

市场调查报告书

商品编码

1958586

互联药物传输设备市场（第三版）：依设备类型、连接方式、给药途径、治疗领域和地区划分 - 趋势与至2035年的预测

Connected Drug Delivery Devices Market (3rd Edition): Distribution by Type of Device, Mode of Connectivity, Route of Administration, Therapeutic Area & Geographical Regions - Trends and Forecast Till 2035

出版日期: 2026年02月17日 | 出版商:

Roots Analysis | 英文 500 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

互联药物传输设备市场 - 概述

全球互联药物输送设备市场预计将从目前的53亿美元成长到2035年的127亿美元，在预测期内（至2035年）的年复合成长率（CAGR）为 10.2%。

互联药物传输设备市场 - 成长与趋势

药物依从性低一直是医疗保健领域的重大挑战，它会导致疾病进展、住院率上升、死亡率升高以及医疗保健成本增加。研究表明，儘管美国约有 66%的人至少获得过一次处方，但约有 50%的人未能按医嘱服药。药物依从性问题源自于多种因素，包括复杂的给药方案、药物取得途径有限、病患支持不足。为了应对这项挑战，医疗保健专业人员和技术提供者采用各种策略，包括简化给药方案、提供个人化给药计画以及加强病患教育。

互联药物输送设备透过将传统给药方式与数位健康技术结合，成为提高用药依从性的有效解决方案。这些设备配备了先进的功能、感测器和无线连接，能够与行动应用程式、数位健康平台和电子健康记录（EHR）无缝整合。此外，互联药物输送系统能够即时追踪药物摄取量和患者健康状况，促进及时的临床干预和个人化治疗方案的调整。透过提高患者参与度和依从性，这些设备不仅能够改善治疗效果，还有助于降低整体医疗保健成本。

此外，感测器技术的整合改变传统药物传输系统的功能，使其发展成为智慧互联的解决方案。远距医疗整合的持续进步和数位健康工具的广泛应用预计将在未来几年推动互联药物输送设备市场持续成长。

成长因素 - 市场扩张的策略驱动因素

糖尿病、气喘、慢性阻塞性肺病（COPD）和自体免疫疾病等慢性病盛行率的上升推动市场需求。这是因为互联药物传输设备能够实现精准的剂量管理和长期治疗管理。感测器技术、低功耗蓝牙、人工智慧分析和物联网整合等方面的技术进步，使得远端监测、与医疗服务提供者的资料共享以及个人化干预成为可能，提高了患者的用药依从性和治疗效果。患者参与度的提高和人口老化进一步推动了市场成长，而与远距医疗的协同作用以及向精准医疗的转变，预计将推动市场实现更高的年复合成长率。

市场挑战 - 发展道路上的重大障碍

互联药物输送设备整合了感测器和应用程序，可实现对糖尿病和哮喘等慢性疾病的即时用药依从性追踪和远端监测，但其面临着多方面的市场挑战，阻碍了其广泛应用。由于先进的感测器、研发、精密组装和供应链问题，高昂的开发和製造成本推高了其价格，使其高于传统设备。此外，持续的云端服务费用、关税和偿付缺口也加剧了这些挑战。此外，药物-设备组合的严格监管障碍和缓慢的全球合规进程与快速的技术进步相衝突，限制了人工智慧的创新。网路安全和资料隐私风险削弱了用户信任，并限制了资料共享。此外，可用性问题等应用障碍依然存在。

互联药物传输设备市场 - 关键洞察

本报告深入分析了互联药物输送设备市场的现状，并指出了该行业的潜在成长机会。主要发现包括：

在当前市场格局中，超过 80 家製造商提供各种互联药物输送设备，其中大多数总部位于北美。
目前约有 75%的互联/智慧药物输送设备已上市，其中大部分设备用于皮下给药。

Connected Drug Delivery Devices Market-IMG1

目前，超过 30 种可与传统药物输送设备整合的创新附加感测器已上市或研发中。这些附加感测器製造商大多是位于欧洲的新创公司。
超过 55%的附加感测器专为吸入式药物输送而设计，其中超过 85%的感测器支援蓝牙连接。
迄今为止，该领域註册的大多数临床试验都在评估各种连网药物传输装置的安全性和有效性，其中许多研究在美国各地多个地点进行。
近年来，各利害关係人之间的合作关係日益增多，反映出利害关係人对该市场的兴趣日益浓厚。事实上，近 70%的交易都是在过去三年内达成的。
投资者正向连网药物输送装置市场投入大量资金，以开发能加速产业发展的先进设备。
连网/智慧型药物传输装置的开发过程包括多个阶段，包括规划、设计、工程、製程验证、製造、组装和商业化。
根据蓝海战略分析中的 "先锋-迁徙-定居者" 地图，未来几年，多家专注于产品改进的互联药物输送设备製造商有望成为行业先锋。

Connected Drug Delivery Devices Market-IMG2

由于互联药物输送设备能够实现精准给药和远端患者监测，预计未来十年该市场将实现显着成长（年复合成长率达10.2%）。

Connected Drug Delivery Devices Market-IMG3

预计到2035年，北美互联药物输送设备市场将占据最大占有率。此外，大多数用于药物传输的设备都针对代谢性疾病。
受美国智慧互联药物输送解决方案日益普及的推动，预计互联药物输送设备市场在预测期内将以更高的年复合成长率成长。
鑑于对先进药物输送设备的需求激增以及慢性病患病率的上升，互联药物输送设备市场预计将稳步扩张。

互联药物传输设备市场

市场规模和机会分析基于以下参数进行细分：

依装置类型

连网/智慧型穿戴注射器
互联/智慧吸入器
互联/智慧注射笔
连网/智慧型自动注射器
互联/智慧型无针注射系统

依连接方式

蓝牙设备
近场通讯设备
蜂巢式网路设备
广域网路设备

依给药途径

肠外给药
吸入给药

依治疗领域

代谢性疾病
呼吸系统疾病
自体免疫疾病
其他疾病

依地区

北美洲
美国
加拿大
欧洲
英国
德国
法国
义大利
西班牙
欧洲其他地区
亚太地区
中国
印度
日本
亚太其他地区

互联药物输送设备市场 - 主要细分市场

连网/智慧型穿戴注射器占据最大市场占有率

连网/智慧型穿戴注射器今年占据了最大的市场占有率，预计这一趋势将在未来几年持续下去。这主要归因于慢性病盛行率的不断上升，以及利害关係人持续致力于将先进功能融入连网药物输送设备。这些改进能够增强监测效果、提高病患依从性，并促进与医疗专业人员的资料交换。

未来蓝牙连网/智慧型装置可望占最大市场占有率

目前，蓝牙连网/智慧型装置预计将占据连网药物传输设备市场更大的占有率。此外，预计该细分市场在预测期内将实现显着成长。这是因为蓝牙连接易于设置，几乎所有智慧型手机都支援此功能，而且无需额外设备即可运作。

今年，肠外给药领域将占据连网药物输送设备市场最大的占有率。

据估计，肠外给药领域今年的市场占有率预计将更大。这是因为肠外给药是生物製剂和慢性病高价值疗法的首选给药途径。此外，吸入给药领域预计在预测期内将维持较高的年复合成长率。这主要归功于吸入给药方式的便利性、多功能性和无痛性，以及其能够提供持续的局部治疗效果。

北美将占据市场主导地位，拥有最大的市场占有率。

根据预测，北美预计在今年继续保持其在互联药物输送设备市场占有率方面的领先地位。此外，预计到2035年，亚太市场将以相对较高的成长率扩张。这一成长得益于生物製药新创企业的增加、创新药物输送系统研发的加强以及该地区人口的成长。这主要得益于互联药物输送设备市场中获准用于治疗各种疾病的设备数量的增加。

互联药物输送设备市场的主要参与者

Bigfoot Biomedical
BIOCORP
Eitan Medical
E3D Elcam Drug Delivery Device
EoFlow
Gerresheimer
Insulet
Medtronic
Medtrum
Nemera
Phillips-Medisize
Roche
Sonceboz
SOOIL Development
Tandem Diabetes Care
West Pharmaceutical Services
Ypsomed

互联药物传输设备市场 - 范围

市场规模和机会分析：本报告对互联药物输送设备市场进行了详细分析。药物输送装置市场，重点关注以下关键细分市场：[A] 装置类型，[B] 连接方式，[C] 给药途径，[D] 治疗领域，以及 [E] 地理区域。
互联/智慧型药物输送装置市场概览：除了对整合式互联药物输送装置的整体市场概览进行详细概述外，还提供以下资讯：[A] 开发阶段，[B] 装置上市年份，[C] 整合装置类型，[D] 给药途径，[E] 目标适应症/治疗领域，[F] 整合装置类型，[D] 给药途径，[E] 目标适应症/治疗领域，[F] 主要功能，[G] 平台的应用方式，[成立年份，[J] 公司规模，[K] 总部所在地，以及 [H] 主要参与者。
附加感测器市场概览：本报告概述了附加感测器市场的整体市场格局，并详细介绍了以下相关参数：[A] 开发阶段，[B] 设备发布年份，[C] 相容设备，[D] 给药途径，[E] 目标适应症/治疗领域，[F] 治疗领域，[G] 目标可适应症，[E] 目标适应症/治疗领域，[F] 治疗领域，[G] 目标可适应症，[HJ] 主要可用性，[KJ]资料储存/云端平台的可用性，[L] 成立年份，[M] 公司规模，[N] 总部所在地，[O] 主要参与者。
产品竞争分析：本报告基于 [A] 製造商优势和 [B] 产品组合优势，对互联药物输送设备和附加感测器进行调查分析。
公司概况：本报告基于以下几个方面，详细介绍了北美、欧洲和亚太地区主要互联药物输送设备製造商的概况：[A] 成立年份，[B] 总部所在地，[C] 产品组合，[D] 近期发展，以及 [E] 未来展望。
临床试验分析：基于以下几个相关参数，分析了已完成和进行的与互联药物输送设备相关的临床试验：[A] 研究註册年份，[B] 入组患者人数，[C] 研究状态，[D] 申办方/合作方类型，[E] 研究设计，以及 [F] 所在地区。
合作关係：基于以下相关参数，分析了利害关係人之间达成的合作关係：[A] 合作年份，[B] 合作类型，[C] 设备分类，[D] 整合设备类型，以及 [E] 最活跃的参与者。
资金/投资分析：基于以下相关参数分析该领域的资金和投资协议：[A] 资金年份，[B] 资金类型，[C] 投资金额，[D] 地区，以及 [E] 主要参与者。
价值链分析：提供连网/智慧药物输送装置开发各阶段的详细价值链分析，例如研发、产品製造/组装、产品分销、行销/销售以及上市后监测，并提供各阶段的成本资讯。
监管环境：概述各国家和地区主要监管机构制定和发布的互联药物输送装置批准指南。
案例研究：针对两种最常见适应症（即气喘和糖尿病）的详细案例研究，包括疾病概述、流行病学、经济负担（因未遵医嘱治疗而造成的经济负担），以及药物输送装置的发展历程和其他目的是提高这些适应症患者治疗依从性的策略概述。
蓝海策略分析：基于蓝海策略，对当前及未来市场进行详细分析。本报告为新兴的互联药物输送设备公司提供策略规划/指南，帮助他们开拓未开发的市场，并提供策略工具，协助其转型蓝海策略，在市场中获得竞争优势。
SWOT 分析：透过 SWOT 分析，深入探讨可能影响连网药物输送设备市场发展的产业相关趋势、机会与挑战。

章节概述
药物依从性
智慧型/互联药物输送装置概述
关键设计特性与开发流程
智慧型/互联药物传输装置的分类
智慧型/互联药物输送装置的监管指南
智慧型/互联药物传输装置的优点和局限性
新冠疫情对智慧/连网药物输送装置的影响产业
未来展望

第7章市场概况：互联/智慧型药物传输设备

章节概述
互联/智慧型药物传输设备：市场概况
互联/智慧型药物传输设备製造商：市场概况

第8章市场概况：附加感知器

章节概述
附加感测器：市场概况
附加感测器製造商：市场概况

第9章产品竞争分析

章节概述
假设和关键参数
研究方法
互联药物输送设备与附加感测器：产品竞争分析

第10章公司简介：北方美国互联/智慧药物传输设备製造商

章节概述
主要互联/智慧型药物传输设备製造商
- Medtronic
- Insulet
- Tandem Diabetes Care
其他厂商
- Bigfoot Biomedical
- Phillips Medisize（Molex旗下子公司）
- West Pharmaceutical Services

第11章公司简介：欧洲互联/智慧药物传输设备製造商

章节概述
主要互联/智慧型药物传输设备製造商
- BIOCORP
- Gerresheimer
- Roche
- Ypsomed
其他厂商
- Nemera
- Sonceboz

第12章公司简介：亚太及其他地区互联/智慧药物传输设备製造商

章节概述
主要互联/智慧型药物传输设备製造商
- Medtrum
- SOOIL Development
- EOFlow
其他厂商
- Eitan Medical
- E3D Elcam Drug Delivery设备

第13章临床试验分析

章节概述
研究范围与方法
互联/智慧型药物传输设备和附加感测器：临床试验分析

第14章伙伴关係与合作

章节概述
合作模式
互联/智慧型药物传输设备：伙伴关係与合作

第15章资金与投资分析

章节概述
资金模式
互联/智慧药物输送设备：资金与投资

第16章价值链分析

章节概述
互联/智慧型药物输送装置：价值链
价值链成本分配

第17章互联/智慧型药物输送装置的监管环境

章节概述
北美组合产品的监理审批
- 美国组合产品的监管审批
- 加拿大组合产品的监理审批
- 墨西哥组合产品的监管审批
欧洲组合产品的监理审批
- 欧盟五国组合产品的监管审批
亚太地区组合产品的监管审批
- 日本组合产品的监管核准
- 中国组合产品的监管核准
- 印度组合产品的监管核准
- 韩国组合产品的监管核准
- 澳洲组合产品的监管批准
中东和北非组合产品的监管批准
- 沙乌地阿拉伯组合产品的监管核准
- 阿拉伯联合大公国组合产品的监管批准
拉丁美洲组合产品的监管批准
- 巴西组合产品的监管核准
- 阿根廷组合产品的监管批准
连网设备：其他安全、有效性和效能
确保收集资料的安全
结论

第18章案例研究：应用互联药物输送装置提高用药依从性

章节概述
个案研究1：糖尿病
案例研究2：气喘

第19章 SWOT分析

第20章蓝海策略

蓝海策略概述

第21章全球互联药物输送设备市场

第22章互联药物输送设备市场（依设备类型划分）

第23章互联药物输送设备市场（以连接方式划分）

第24章互联药物输送设备市场（依给药途径划分）

第25章互联药物输送设备市场（依治疗领域划分）

第26章互联药物输送设备市场（依地区划分）

第27章互联药物输送设备市场（依主要厂商划分）

第28 结论

第29章高层洞察

第30章附录1：表格资料

第31章附录2：公司与组织清单

第32章附录3：2015-2020年合作伙伴关係

简介目录图表

Product Code: RA100512

Connected Drug Delivery Devices Market: Overview

As per Roots Analysis, the global connected drug delivery market is estimated to grow from USD 5.3 billion in the current year to USD 12.7 billion by 2035, at a CAGR of 10.2% during the forecast period, till 2035.

Connected Drug Delivery Devices Market: Growth and Trends

Over the years, poor compliance to prescribed medications continues to be a significant issue in the healthcare field, leading to disease progression, increased hospitalization rates, mortality, and rising healthcare expenses. Studies indicate that approximately 66% of individuals in the United States receive at least one prescription, yet nearly 50% fail to adhere to their physicians' instructions for medication use. This challenge of non-adherence arises from multiple factors, such as complicated dosing regimens, restricted access to medications, and inadequate patient assistance. To address this, healthcare professionals and technology providers are using various strategies to streamline dosage plans, provide individualized medication schedules, and improve patient education.

Connected drug delivery devices represent a viable solution as these devices integrate traditional delivery methods with digital health technologies to improve adherence. These devices come with advanced features, sensors, and wireless connectivity that allow for smooth integration with mobile apps, digital health platforms, and electronic health records. Additionally, the linked drug delivery system allows for real-time tracking of medication consumption and patient health conditions, thus facilitating prompt clinical interventions and customized therapy modifications. By enhancing patient involvement and adherence, these devices not only bolster patient results but also help in reducing total healthcare costs.

Further, the integration of sensor technologies has transformed the capabilities of conventional drug delivery systems, allowing them to evolve into intelligent, interconnected solutions. Ongoing advancements in telehealth integration and broader acceptance of digital health tools are anticipated to fuel consistent growth in the connected drug delivery device market in the upcoming years.

Growth Drivers: Strategic Enablers of Market Expansion

Rising chronic disease prevalence, including diabetes, asthma, chronic obstructive pulmonary disease (COPD), and autoimmune disorders, fuels demand. This is due to the fact that connected drug delivery devices enable precise dosing and long-term therapy management. Technological advances in sensors, Bluetooth Low Energy, AI analytics, and IoT integration allow remote monitoring, data sharing with providers, and personalized interventions, boosting adherence and outcomes. Patient engagement and aging populations further accelerate growth, with market projections showing a higher CAGR driven by telehealth synergies and precision medicine shifts.

Market Challenges: Critical Barriers Impeding Progress

Connected drug delivery devices, which integrate sensors and apps for real-time adherence tracking and remote monitoring in chronic conditions like diabetes and asthma, face multifaceted market challenges that hinder their widespread adoption. High development and manufacturing costs driven by advanced sensors, R&D, precision assembly, and supply chain issues elevate prices above traditional devices, compounded by ongoing cloud fees, tariffs, and payer reimbursement gaps. Further, stringent regulatory hurdles for drug-device combinations and global compliance delays, clash with rapid tech evolution and limit AI innovations. In addition, cybersecurity and data privacy risks hamper user trust and restrict data sharing, while usage barriers like usability issues persist.

Connected Drug Delivery Devices Market: Key Insights

The report delves into the current state of the connected drug delivery devices market and identifies potential growth opportunities within industry. Some key findings from the report include:

The current market landscape features the presence of more than 80 manufacturers that offer various connected drug delivery devices; of these, majority are headquartered in North America.
Nearly 75% of the connected / smart drug delivery devices are currently commercially available; notably, most of these devices are intended for the administration of medications via subcutaneous route.

At present, over 30 innovative add-on sensors are available / under development for integration with conventional drug delivery devices; numerous add-on sensor manufacturers are start-ups based in Europe.
More than 55% of the add-on sensors are designed for drug delivery via inhalation; of these, over 85% of the sensors can support Bluetooth connectivity.
The majority of clinical trials registered in this domain till date have evaluated the safety and efficacy of various connected drug delivery devices; most of these studies have been conducted across multiple sites in the US.
The growing interest of stakeholders in this market is reflected from the rising partnerships established among various stakeholders in the recent past; in fact, close to 70% of the deals were inked in the last three years.
Investors are increasingly channelizing capital into connected drug delivery devices market for the development of advanced devices which are accelerating industry advancements.
The development process of a connected / smart drug delivery device involves various steps, ranging from planning, designing, engineering, process validation, manufacturing and assembly to commercialization.
The pioneer-migrator-settler map in blue ocean strategy analysis suggests that several connected drug delivery devices manufacturers focused on enhancing their products are likely to emerge as pioneers in the coming years.

Owing to the ability of connected drug delivery devices to provide precise dosing and remote patient monitoring, the market is anticipated to witness a notable growth (CAGR of 10.2%) over the next decade.

The connected drug delivery devices market in North America is expected to capture maximum share by 2035; further, majority of the devices manufactured for drug delivery are intended for metabolic disorders.
Driven by the growing adoption of smart and connected drug delivery solutions in the US, the connected drug delivery devices market is poised to grow at a higher CAGR over the forecast period.
Given the surge in demand for advanced drug delivery devices and the rising prevalence of chronic diseases, the connected drug delivery devices market is anticipated to rise steadily.

Connected Drug Delivery Devices Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Device

Connected / Smart Wearable Injectors
Connected / Smart Inhalers
Connected / Smart Pen Injectors
Connected / Smart Autoinjectors
Connected / Smart Needle-free Injection Systems

By Mode of Connectivity

Bluetooth-enabled Devices
Near Field Communication-enabled Devices
Cellular-enabled Devices
Wide Area Network-enabled Devices

By Route of Administration

Parenteral
Inhalational

By Therapeutic Area

Metabolic Disorders
Respiratory Disorders
Autoimmune Disorders
Other Disorders

By Geographical Regions

North America
US
Canada
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Rest of Asia-Pacific

Connected Drug Delivery Devices Market: Key Segments

Connected / Smart Wearable Injectors Account for the Largest Market Share

In the current year, the connected / smart wearable injectors holds the largest market share, and this trend is expected to persist in the coming years. This is due to the increasing prevalence of chronic diseases and the ongoing initiatives of stakeholders to incorporate enhanced features into their connected drug delivery devices. These improvements enhance monitoring, strengthen patient compliance, and allow data exchange with healthcare professionals.

Bluetooth-Enabled Connected / Smart Devices Hold the Highest Share in the Future

At present, Bluetooth-enabled connected / smart devices are expected to capture a larger share of the connected drug delivery devices market. Moreover, this segment is expected to experience substantial growth during the forecasted period. This is because Bluetooth connectivity is simple to set up, widely accessible on all smartphones, and operates without requiring any additional devices.

Parenteral Segment Holds the Highest Connected Drug Delivery Devices Market Share in the Current Year

According to our estimates, in the current year, the parenteral segment is likely to hold a larger market share. This is because it is the favored route for administering biologics and high-value treatments for chronic conditions. Further, the inhalation segment is expected to experience a higher CAGR over the forecast period, owing to the ease, versatility, and painless nature of drug delivery through this method, along with its ability for prolonged localized therapeutic effect.

North America Dominates the Market by Securing Highest Share

According to our estimates, North America is expected to dominate the connected drug delivery devices market share this year. Further, the Asia-Pacific market is expected to expand at a comparatively higher rate till 2035. The growth is driven by a rising number of biopharmaceutical start-ups, significant research and development efforts for innovative drug delivery systems, and an increase in device approvals for various disease therapies in this area.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:

Senior Director, Global Strategic Marketing, Medical, Large Company, US
Co-Founder and Chief Executive Officer, Small Company, US
Chief Executive Officer, Small Company, US
Chief Executive Officer and President, Mid-sized Company, US
Chief Executive Officer, Small Company, Italy
Vice President and Chief Scientist, Large Company, Israel
Director of Global Communications, and Former Vice President of Strategic Partnerships and Business Development, Mid-sized Company, US
Former Chief Executive Officer, Small Company, US
Former Director of Front-end Innovation and Head of Connected Health, Large Company, US
Former Vice President, Marketing and Alliance Management, Mid-sized Company, US
Advisor of Strategy and Business Development, Small Company, US

Example Players in Connected Drug Delivery Devices Market

Bigfoot Biomedical
BIOCORP
Eitan Medical
E3D Elcam Drug Delivery Device
EoFlow
Gerresheimer
Insulet
Medtronic
Medtrum
Nemera
Phillips-Medisize
Roche
Sonceboz
SOOIL Development
Tandem Diabetes Care
West Pharmaceutical Services
Ypsomed

Connected Drug Delivery Devices Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the connected drug delivery devices market, focusing on key market segments, including [A] type of device [B] mode of connectivity, [C] route of administration, [D] therapeutic area, and [E] geographical regions.
Connected / Smart Drug Delivery Devices Market Landscape: A detailed overview of the overall market landscape of integrated connected drug delivery devices, along with information on several relevant parameters, such as [A] stage of development, [B] launch year of device, [C] type of integrated device, [D] route of administration, [E] target indication, therapeutic area, [F] key features, [G] mode of connectivity, [H] availability of companion mobile application and availability of data storage / cloud platform, [I] year of establishment, [J] company size, [K] location of headquarters and [H] most active players.
Add-On Sensors Market Landscape: : A detailed overview overall market landscape of add-on sensors market landscape, along with information on several relevant parameters, such as [A] stage of development, [B] launch year of device, [C] compatible device, [D] route of administration, [E] target indication, [F] therapeutic area, [G] target indication, [H] key features, [I] mode of connectivity, [J] availability of companion mobile application and [K] availability of data storage / cloud platform, [L] year of establishment, [M] company size, [N] location of headquarters and [O] most active players.
Product Competitiveness Analysis: An insightful analysis of connected drug delivery devices and add-on sensors based on the [A] manufacturer strength and [B] portfolio strength.
Company Profiles: In-depth profiles of leading players manufacturing connected drug delivery devices in North America, Europe and Asia-Pacific based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
Clinical Trial Analysis: An analysis of completed and ongoing clinical trials related to connected drug delivery devices, based on several relevant parameters, such as [A] trial registration year, [B] enrolled patient population, [C] trial status, [D] type of sponsor / collaborator, [E] study design [F] and geography.
Partnerships and Collaborations: An analysis of partnerships and collaborations inked between stakeholders, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] class of device, [D] type of integrated device, [E] most active players.
Funding and Investment Analysis: An analysis of funding and investment signed in the domain based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount invested, [D] geography, [E] and most active players.
Value Chain Analysis: An in-depth value chain analysis featuring a discussion on various steps involved in the development of connected / smart drug delivery devices, including research and development (R&D), product manufacturing and assembly, product distribution, marketing and sales, and post-market surveillance, along with the information on cost requirements across each of the aforementioned stages.
Regulatory Landscape: An informative summary of various guidelines established and issued by major regulatory bodies for the approval of connected drug delivery devices, across different countries / geographical regions.
Case Studies: Detailed case studies on two most common indications (namely asthma and diabetes), featuring a brief description of the disease, its epidemiology, economic burden (imposed due to non-adherence to prescribed treatments), and a summary of the evolution of drug delivery devices and other strategies focused on improving therapy adherence among patients suffering from the indication.
Blue Ocean Analysis: A detailed analysis of the current and future market based on blue ocean strategy, covering a strategic plan / guide for emerging connected drug delivery device companies to help unlock an uncontested market, featuring strategic tools that can help them to shift towards a blue ocean in order to gain a competitive edge in the market.
SWOT Analysis: A detailed discussion on industry affiliated trends, opportunities and challenges, under a SWOT analysis, which are likely to impact the evolution of connected drug delivery devices market.

Key Questions Answered in this Report

Which are the leading companies in connected drug delivery devices market?
Which region dominates the connected drug delivery devices market?
What are the key trends observed in the connected drug delivery devices market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by connected drug delivery device developers?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

Complementary PPT Insights Pack
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Medication Adherence
- 6.2.1. Digital Tools for Improving Medication Adherence
6.3. Overview of Connected / Smart Drug Delivery Devices
6.4. Key Design Features and Development Process
6.5. Classification of Connected / Smart Drug Delivery Devices
- 6.5.1. Type of Device
  - 6.5.1.1. Connected Inhalers
  - 6.5.1.2. Connected Handheld Injectors
  - 6.5.1.3. Smart Pills
  - 6.5.1.4. Smart Implantable Devices
- 6.5.2. Type of Technology
6.6. Regulatory Guidelines for Connected / Smart Drug Delivery Devices
6.7. Advantages and Limitations of Connected / Smart Drug Delivery Devices
6.8. Impact of COVID-19 on Connected / Smart Drug Delivery Devices Domain
6.9. Future Perspective

7. MARKET LANDSCAPE: CONNECTED / SMART DRUG DELIVERY DEVICES

7.1. Chapter Overview
7.2. Connected / Smart Drug Delivery Devices: Overall Market Landscape
- 7.2.1. Analysis by Stage of Development
- 7.2.2. Analysis by Launch Year
- 7.2.3. Analysis by Type of Integrated Device
- 7.2.4. Analysis by Route of Administration
- 7.2.5. Analysis by Target Indication
- 7.2.6. Analysis by Therapeutic Area
- 7.2.7. Analysis by Key Features
- 7.2.8. Analysis by Mode of Connectivity
- 7.2.9. Analysis by Availability of Companion Mobile Application
- 7.2.10. Analysis by Availability of Data Storage / Cloud Platform
7.3. Connected / Smart Drug Delivery Device Manufacturers: Overall Market Landscape
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters
- 7.3.4. Analysis by Year of Establishment and Location of Headquarters
- 7.3.5. Analysis by Company Size and Location of Headquarters
- 7.3.6. Most Active Players: Analysis by Number of Connected / Smart Drug Delivery Devices Manufactured

8. MARKET LANDSCAPE: ADD-ON SENSORS

8.1. Chapter Overview
8.2. Add-on Sensors: Overall Market Landscape
- 8.2.1. Analysis by Stage of Development
- 8.2.2. Analysis by Launch Year
- 8.2.3. Analysis by Compatible Device
- 8.2.4. Analysis by Route of Administration
- 8.2.5. Analysis by Target Indication
- 8.2.6. Analysis by Therapeutic Area
- 8.2.7. Analysis by Key Features
- 8.2.8. Analysis by Mode of Connectivity
- 8.2.9. Analysis by Availability of Companion Mobile Application
- 8.2.10. Analysis by Availability of Data Storage / Cloud Platform
8.3. Add-on Sensor Manufacturers: Overall Market Landscape
- 8.3.1. Analysis by Year of Establishment
- 8.3.2. Analysis by Company Size
- 8.3.3. Analysis by Location of Headquarters
- 8.3.4. Analysis by Year of Establishment and Location of Headquarters
- 8.3.5. Analysis by Company Size and Location of Headquarters
- 8.3.6. Most Active Players: Analysis by Number of Add-on Sensors Manufactured

9. PRODUCT COMPETITIVENESS ANALYSIS

9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Connected Drug Delivery Devices and Add-on Sensors: Product Competitiveness Analysis
- 9.4.1. Connected / Smart Drug Delivery Devices
  - 9.4.1.1. Smart Handheld Injectors (Peer Group 1a)
  - 9.4.1.2. Smart Wearable Injectors (Peer Group 1b)
  - 9.4.1.3. Other Integrated Devices (Peer Group 1c)
- 9.4.2. Add-on Sensors (Peer Group 2)

10. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN NORTH AMERICA

10.1. Chapter Overview
10.2. Leading Connected / Smart Drug Delivery Device Manufacturers
- 10.2.1. Medtronic
  - 10.2.1.1. Company Overview
  - 10.2.1.2. Financial Information
  - 10.2.1.3. Connected / Smart Drug Delivery Devices Portfolio
  - 10.2.1.4. Recent Developments and Future Outlook
- 10.2.2. Insulet
  - 10.2.2.1. Company Overview
  - 10.2.2.2. Financial Information
  - 10.2.2.3. Connected / Smart Drug Delivery Devices Portfolio
  - 10.2.2.4. Recent Developments and Future Outlook
- 10.2.3. Tandem Diabetes Care
  - 10.2.3.1. Company Overview
  - 10.2.3.2. Financial Information
  - 10.2.3.3. Connected / Smart Drug Delivery Devices Portfolio
  - 10.2.3.4. Recent Developments and Future Outlook
10.3. Other Prominent Connected / Smart Drug Delivery Device Manufacturers
- 10.3.1. Bigfoot Biomedical
  - 10.3.1.1. Company Overview
  - 10.3.1.2. Connected / Smart Drug Delivery Devices Portfolio
- 10.3.2. Phillips Medisize (a subsidiary of Molex)
  - 10.3.2.1. Company Overview
  - 10.3.2.2. Connected / Smart Drug Delivery Devices Portfolio
- 10.3.3. West Pharmaceutical Services
  - 10.3.3.1. Company Overview
  - 10.3.3.2. Connected / Smart Drug Delivery Devices Portfolio

11. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN EUROPE

11.1. Chapter Overview
11.2. Leading Connected / Smart Drug Delivery Device Manufacturers
- 11.2.1. BIOCORP
  - 11.2.1.1. Company Overview
  - 11.2.1.2. Financial Information
  - 11.2.1.3. Connected / Smart Drug Delivery Devices Portfolio
  - 11.2.1.4. Recent Developments and Future Outlook
- 11.2.2. Gerresheimer
  - 11.2.2.1. Company Overview
  - 11.2.2.2. Financial Information
  - 11.2.2.3. Connected / Smart Drug Delivery Devices Portfolio
  - 11.2.2.4. Recent Developments and Future Outlook
- 11.2.3. Roche
  - 11.2.3.1. Company Overview
  - 11.2.3.2. Financial Information
  - 11.2.3.3. Connected / Smart Drug Delivery Devices Portfolio
  - 11.2.3.4. Recent Developments and Future Outlook
- 11.2.4. Ypsomed
  - 11.2.4.1. Company Overview
  - 11.2.4.2. Financial Information
  - 11.2.4.3. Connected / Smart Drug Delivery Devices Portfolio
  - 11.2.4.4. Recent Developments and Future Outlook
11.3. Other Prominent Connected / Smart Drug Delivery Device Manufacturers
- 11.3.1. Nemera
  - 11.3.1.1. Company Overview
  - 11.3.1.2. Connected / Smart Drug Delivery Devices Portfolio
- 11.3.2. Sonceboz
  - 11.3.2.1. Company Overview
  - 11.3.2.2. Connected / Smart Drug Delivery Devices Portfolio

12. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD

12.1. Chapter Overview
12.2. Leading Connected / Smart Drug Delivery Device Manufacturers
- 12.2.1. Medtrum
  - 12.2.1.1. Company Overview
  - 12.2.1.2. Connected / Smart Drug Delivery Devices Portfolio
  - 12.2.1.3. Recent Developments and Future Outlook
- 12.2.2. SOOIL Development
  - 12.2.2.1. Company Overview
  - 12.2.2.2. Connected / Smart Drug Delivery Devices Portfolio
  - 12.2.2.3. Recent Developments and Future Outlook
- 12.2.3. EOFlow
  - 12.2.3.1. Company Overview
  - 12.2.3.2. Financial Information
  - 12.2.3.3. Connected / Smart Drug Delivery Devices Portfolio
  - 12.2.3.4. Recent Developments and Future Outlook
12.3. Other Prominent Connected / Smart Drug Delivery Device Manufacturers
- 12.3.1. Eitan Medical
  - 12.3.1.1. Company Overview
  - 12.3.1.2. Connected / Smart Drug Delivery Devices Portfolio
- 12.3.2. E3D Elcam Drug Delivery Device
  - 12.3.2.1. Company Overview
  - 12.3.2.2. Connected / Smart Drug Delivery Devices Portfolio

13. CLINICAL TRIAL ANALYSIS

13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Connected / Smart Drug Delivery Devices and Add-on Sensors: Clinical Trial Analysis
- 13.3.1. Analysis by Trial Registration Year
- 13.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
- 13.3.3. Analysis by Trial Status
- 10.3.4. Analysis by Trial Registration Year and Trial Status
- 13.3.5. Analysis of Number of Enrolled Patients Population by Trial Status
- 13.3.6. Analysis by Target Patient Population
- 13.3.7. Analysis by Type of Sponsor / Collaborator
- 13.3.8. Analysis by Study Design
  - 10.3.8.1. Analysis by Type of Allocation
  - 10.3.8.2. Analysis by Type of Intervention Model
  - 10.3.8.3. Analysis by Type of Masking
  - 10.3.8.4. Analysis by Trial Purpose
- 13.3.9. Leading Players: Analysis by Number of Registered Trials
- 13.3.10. Leading Connected / Smart Drug Delivery Devices and Add-on Sensors: Analysis by Number of Registered Trials
- 13.3.11. Analysis by Geography
  - 13.3.11.1. Analysis of Clinical Trials by Geography
  - 13.3.11.2. Analysis of Number of Registered Trials by Trial Status and Geography
  - 13.3.11.3. Analysis of Number of Enrolled Patient Population by Geography

14. PARTNERSHIPS AND COLLABORATIONS

14.1. Chapter Overview
14.2. Partnership Models
14.3. Connected / Smart Drug Delivery Devices: Partnerships and Collaborations
- 14.3.1. Analysis by Year of Partnership
- 14.3.2. Analysis by Type of Partnership
- 14.3.3. Analysis by Year and Type of Partnership
- 14.3.4. Analysis by Class of Device
- 14.3.5. Analysis by Type of Integrated Device
- 14.3.6. Most Active Players: Analysis by Number of Partnerships
- 14.3.7. Analysis by Geography
  - 14.3.7.1. Intracontinental and Intercontinental Deals
  - 14.3.7.2. Local and International Deals

15. FUNDING AND INVESTMENT ANALYSIS

15.1. Chapter Overview
15.2. Funding Models
15.3. Connected / Smart Drug Delivery Devices: Funding and Investments
- 15.3.1. Analysis by Year of Funding
- 15.3.2. Analysis by Type of Funding
- 15.3.3. Analysis by Year and Type of Funding
- 15.3.4. Analysis of Amount Invested by Year of Funding
- 15.3.5. Analysis of Amount Invested by Type of Funding
- 15.3.6. Analysis by Geography
- 15.3.7. Most Active Players: Analysis by Number of Funding Instances
- 15.3.8. Most Active Players: Analysis by Amount Raised

16. VALUE CHAIN ANALYSIS

16.1. Chapter Overview
16.2. Connected / Smart Drug Delivery Devices: Value Chain
16.3. Cost Distribution across the Value Chain
- 16.3.1. Concept Development and Proof of Concept
- 16.3.2. Research and Product Development
- 16.3.3. Conduct of Clinical Trials
- 16.3.4. Regulatory Approvals
- 16.3.5. Manufacturing and Product Assembly
- 16.3.6. Application Development
- 16.3.7. Marketing and Sales

17. REGULATORY LANDSCAPE FOR CONNECTED / SMART DRUG DELIVERY DEVICES

17.1. Chapter Overview
17.2. Regulatory Approval of Combination Products in North America
- 17.2.1. Regulatory Approval of Combination Products in the US
  - 17.2.1.1. Overview
  - 17.2.1.2. Historical Background
  - 17.2.1.3. Role of Regulatory Bodies in Product Approval
- 17.2.2. Regulatory Approval of Combination Products in Canada
  - 17.2.2.1. Overview
  - 17.2.2.2. Role of Regulatory Bodies in Product Approval
- 17.2.3. Regulatory Approval of Combination Products in Mexico
  - 17.2.3.1. Overview
  - 17.2.3.2. Role of Regulatory Bodies in Product Approval
17.3. Regulatory Approval of Combination Products in Europe
- 17.3.1. Regulatory Approval of Combination Products in EU5 Countries
  - 17.3.1.1. Overview
  - 17.3.1.2. Role of Regulatory Bodies in Product Approval
17.4. Regulatory Approval of Combination Products in Asia-Pacific
- 17.4.1. Regulatory Approval of Combination Products in Japan
  - 17.4.1.1. Overview
  - 17.4.1.2. Role of Regulatory Bodies in Product Approval
- 17.4.2. Regulatory Approval of Combination Products in China
  - 17.4.2.1. Overview
  - 17.4.2.2. Role of Regulatory Bodies in Product Approval
- 17.4.3. Regulatory Approval of Combination Products in India
  - 17.4.3.1. Overview
  - 17.4.3.2. Role of Regulatory Bodies in Product Approval
- 17.4.4. Regulatory Approval of Combination Products in South Korea
  - 17.4.4.1. Overview
  - 17.4.4.2. Role of Regulatory Bodies in Product Approval
- 17.4.5. Regulatory Approval of Combination Products in Australia
  - 17.4.5.1. Overview
  - 17.4.5.2. Role of Regulatory Bodies in Product Approval
17.5. Regulatory Approval of Combination Products in Middle East and North Africa
- 17.5.1. Regulatory Approval of Combination Products in Saudi Arabia
  - 17.5.1.1. Overview
  - 17.5.1.2. Role of Regulatory Bodies in Product Approval
- 17.5.2. Regulatory Approval of Combination Products in United Arab Emirates
  - 17.5.2.1. Overview
  - 17.5.2.2. Role of Regulatory Bodies in Product Approval
17.6. Regulatory Approval of Combination Products in Latin America
- 17.6.1. Regulatory Approval of Combination Products in Brazil
  - 17.6.1.1. Overview
  - 17.6.1.2. Role of Regulatory Bodies in Product Approval
- 17.6.2. Regulatory Approval of Combination Products in Argentina
  - 17.6.2.1. Overview
  - 17.6.2.2. Role of Regulatory Bodies in Product Approval
17.7. Connected Devices: Other Measures for Testing Safety, Effectiveness and Performance
17.8. Ensuring Security of Data Captured
17.9. Concluding Remarks

18. CASE STUDIES: APPLICATION OF CONNECTED DRUG DELIVERY DEVICES TO IMPROVE MEDICATION ADHERENCE

18.1. Chapter Overview
18.2. Case Study I: Diabetes
- 18.2.1. Disease Overview
- 18.2.2. Key Statistics
- 18.2.3. Economic Burden due to Non-Adherence
- 18.2.4. Evolution of Connected / Smart Drug Delivery Devices for Improving Adherence
18.3. Case Study II: Asthma
- 18.3.1. Disease Overview
- 18.3.2. Key Statistics
- 18.3.3. Economic Burden due to Non-Adherence
- 18.3.4. Evolution of Connected / Smart Drug Delivery Devices for Improving Adherence

19. SWOT ANALYSIS

19.1. Chapter Overview
19.2. Strengths
- 19.2.1. Ability to Minimize / Eliminate Medication Errors
- 19.2.2. Economic Advantages
- 19.2.3. Technological Advancements
19.3. Weaknesses
- 19.3.1. Cybersecurity
- 19.3.2. Stringent Regulatory Approvals
- 19.3.3. High Developmental Costs
19.4. Opportunities
- 19.4.1. Growing Prevalence of Chronic Disorders
- 19.4.2. Increasing Adoption of Digital Health Technologies
- 19.4.3. Rising Partnership and Investment Activity
19.5. Threats
- 19.5.1. Material Compatibility Issues
- 19.5.2. Availability of Alternative Drug Delivery Devices
- 19.5.3. Concern Related to Product Recalls in Past
19.6. Comparison of SWOT Factors

20. BLUE OCEAN STRATEGY

20.1. Overview of Blue Ocean Strategy
- 20.1.1. Red Oceans
- 20.1.2. Blue Oceans
- 20.1.3. Comparison of Red Ocean Strategy and Blue Ocean Strategy
- 20.1.4. Connected Drug Delivery Devices: Blue Ocean Strategy and Shift Tools
  - 20.1.4.1. Strategy Canvas
  - 20.1.4.2. Pioneer-Migrator-Settler (PMS) Map

21. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET

21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Global Connected Drug Delivery Devices Market: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 21.3.1. Scenario Analysis
  - 21.3.1.1. Conservative Scenario
  - 21.3.1.2. Optimistic Scenario
21.4. Key Market Segmentations

22. CONNECTED DRUG DELIVERY DEVICES MARKET, BY TYPE OF DEVICE

22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Connected Drug Delivery Devices Market: Distribution by Type of Device
- 22.3.1. Connected Drug Delivery Devices Market for Connected / Smart Wearable Injectors: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 22.3.2. Connected Drug Delivery Devices Market for Connected / Smart Inhalers: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 22.3.3. Connected Drug Delivery Devices Market for Connected / Smart Pen Injectors: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 22.3.4. Connected Drug Delivery Devices Market for Connected / Smart Autoinjectors: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 22.3.5. Connected Drug Delivery Devices Market for Connected / Smart Needle-free Injection Systems: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation

23. CONNECTED DRUG DELIVERY DEVICES MARKET, BY MODE OF CONNECTIVITY

23.1. Chapter Overview
23.2. Assumptions and Methodology
23.3. Connected Drug Delivery Devices Market: Distribution by Mode of Connectivity
- 23.3.1. Connected Drug Delivery Devices Market for Bluetooth-enabled Devices: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 23.3.2. Connected Drug Delivery Devices Market for Near-field Communication-enabled Devices: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 23.3.3. Connected Drug Delivery Devices Market for Cellular-enabled Devices: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 23.3.4. Connected Drug Delivery Devices Market for Wide Area Network-enabled Devices: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation

24. CONNECTED DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION

24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Connected Drug Delivery Devices Market: Distribution by Route of Administration
- 24.3.1. Connected Drug Delivery Devices Market for Parenteral Administration: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 24.3.2. Connected Drug Delivery Devices Market for Inhalational Administration: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
24.4. Data Triangulation and Validation

25. CONNECTED DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC AREA

25.1. Chapter Overview
25.2. Assumptions and Methodology
25.3. Connected Drug Delivery Devices Market: Distribution by Therapeutic Area
- 25.3.1. Connected Drug Delivery Devices Market for Metabolic Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 25.3.2. Connected Drug Delivery Devices Market for Respiratory Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 25.3.3. Connected Drug Delivery Devices Market for Autoimmune Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 25.3.4. Connected Drug Delivery Devices Market for Other Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation

26. CONNECTED DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHICAL REGIONS

26.1. Chapter Overview
26.2. Assumptions and Methodology
26.3. Connected Drug Delivery Devices Market: Distribution by Geographical Regions
- 26.3.1. Connected Drug Delivery Devices Market in North America: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.1.1. Connected Drug Delivery Devices Market in the US: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.1.2. Connected Drug Delivery Devices Market in Canada: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 26.3.2. Connected Drug Delivery Devices Market in Europe: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.1. Connected Drug Delivery Devices Market in the UK: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.2. Connected Drug Delivery Devices Market in Germany: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.3. Connected Drug Delivery Devices Market in France: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.4. Connected Drug Delivery Devices Market in Italy: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.5. Connected Drug Delivery Devices Market in Spain: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.6. Connected Drug Delivery Devices Market in Rest of Europe: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 26.3.3. Connected Drug Delivery Devices Market in Asia-Pacific: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.3.1. Connected Drug Delivery Devices Market in China: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.3.2. Connected Drug Delivery Devices Market in India: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.3.3. Connected Drug Delivery Devices Market in Japan: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.3.4. Connected Drug Delivery Devices Market in Rest of Asia-Pacific: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 26.3.4. Connected Drug Delivery Devices Market in Middle East and North Africa: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.4.1. Connected Drug Delivery Devices Market in Egypt: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.4.2. Connected Drug Delivery Devices Market in Israel: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.4.3. Connected Drug Delivery Devices Market in Saudi Arabia: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.4.4. Connected Drug Delivery Devices Market in Rest of Middle East and North Africa: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 26.3.5. Connected Drug Delivery Devices Market in Latin America and Rest of the World: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.5.1. Connected Drug Delivery Devices Market in Brazil: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.5.2. Connected Drug Delivery Devices Market in Argentina: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.5.3. Connected Drug Delivery Devices Market in Other Countries: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
26.4. Data Triangulation and Validation

27. CONNECTED DRUG DELIVERY DEVICES MARKET, BY LEADING PLAYERS

28. CONCLUDING REMARKS

29. EXECUTIVE INSIGHTS

30. APPENDIX 1: TABULATED DATA

31. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

32. APPENDIX 3: PARTNERSHIPS AND COLLABORATIONS, 2015-2020

简介目录图表

List of Tables

Table 7.1 Connected / Smart Drug Delivery Devices: Information on Manufacturer, Stage of Development, Launch Year, Type of Integrated Device and Route of Administration
Table 7.2 Connected / Smart Drug Delivery Devices: Information on Therapeutic Area, Target Indication and Key Features
Table 7.3 Connected / Smart Drug Delivery Devices: Information on Mode of Connectivity, Availability of Companion Mobile Application, Compatible Operating System and Availability of Data Storage / Cloud Platform
Table 7.4 Connected / Smart Drug Delivery Devices: Information on Regulatory Approvals, Geographical Reach and Compatible Drug
Table 7.5 Connected / Smart Drug Delivery Device Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 8.1 Add-on Sensors: Information on Manufacturer, Stage of Development, Launch Year, Type of Integrated Device and Route of Administration
Table 8.2 Add-on Sensors: Information on Therapeutic Area, Target Indication and Key Features
Table 8.3 Add-on Sensors: Information on Mode of Connectivity, Availability of Companion Mobile Application, and Availability of Data Storage / Cloud Platform
Table 8.4 Add-on Sensors: Information on Regulatory Approval, Geographical Reach and Drug Delivered
Table 8.5 Add-on Sensor Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 9.1 Product Competitiveness Analysis: Connected / Smart Drug Delivery Devices
Table 10.1 Connected / Smart Drug Delivery Device Manufacturers in North America: List of Companies Profiled
Table 10.2 Medtronic: Company Overview
Table 10.3 Medtronic: Connected / Smart Drug Delivery Devices Portfolio
Table 10.4 Medtronic: Recent Developments and Future Outlook
Table 10.5 Insulet: Company Overview
Table 10.6 Insulet: Connected / Smart Drug Delivery Devices Portfolio
Table 10.7 Insulet: Recent Developments and Future Outlook
Table 10.8 Tandem Diabetes Care: Company Overview
Table 10.9 Tandem Diabetes Care: Connected / Smart Drug Delivery Devices Portfolio
Table 10.10 Tandem Diabetes Care: Recent Developments and Future Outlook
Table 10.11 Bigfoot Biomedical: Company Overview
Table 10.12 Bigfoot Biomedical: Connected / Smart Drug Delivery Devices Portfolio
Table 10.13 Phillips-Medsize (a subsidiary of Molex): Company Overview
Table 10.14 Phillips-Medsize (a subsidiary of Molex): Connected / Smart Drug Delivery Devices Portfolio
Table 10.15 West Pharmaceutical Services: Company Overview
Table 10.16 West Pharmaceutical Services: Connected / Smart Drug Delivery Devices Portfolio
Table 11.1 Connected / Smart Drug Delivery Device Manufacturers in Europe: List of Companies Profiled
Table 11.2 BIOCORP: Company Overview
Table 11.3 BIOCORP: Connected / Smart Drug Delivery Devices Portfolio
Table 11.4 BIOCORP: Recent Developments and Future Outlook
Table 11.5 Gerresheimer: Company Overview
Table 11.6 Gerresheimer: Connected / Smart Drug Delivery Devices Portfolio
Table 11.7 Gerresheimer: Recent Developments and Future Outlook
Table 11.8 Roche: Company Overview
Table 11.9 Roche: Connected / Smart Drug Delivery Devices Portfolio
Table 11.10 Roche: Recent Developments and Future Outlook
Table 11.11 Ypsomed: Company Overview
Table 11.12 Ypsomed: Connected / Smart Drug Delivery Devices Portfolio
Table 11.13 Ypsomed: Recent Developments and Future Outlook
Table 11.14 Nemera: Company Overview
Table 11.15 Nemera: Connected / Smart Drug Delivery Devices Portfolio
Table 11.16 Sonceboz: Company Overview
Table 11.17 Sonceboz: Connected / Smart Drug Delivery Devices Portfolio
Table 12.1 Connected / Smart Drug Delivery Device Manufacturers in Asia-Pacific and Rest of the World: List of Companies Profiled
Table 12.2 Medtrum: Company Overview
Table 12.3 Medtrum: Connected / Smart Drug Delivery Devices Portfolio
Table 12.4 SOOIL Development: Company Overview
Table 12.5 SOOIL Development: Connected / Smart Drug Delivery Devices Portfolio
Table 12.6 SOOIL Development: Recent Developments and Future Outlook
Table 12.7 EOFlow: Company Overview
Table 12.8 EOFlow: Connected / Smart Drug Delivery Devices Portfolio
Table 12.9 EOFlow: Recent Developments and Future Outlook
Table 12.10 Eitan Medical: Company Overview
Table 12.11 Eitan Medical: Connected / Smart Drug Delivery Devices Portfolio
Table 12.12 E3D Elcam Drug Delivery Device: Company Overview
Table 12.13 E3D Elcam Drug Delivery Device: Connected / Smart Drug Delivery Devices Portfolio
Table 14.1 Connected / Smart Drug Delivery Devices: List of Partnerships and Collaborations, since 2021
Table 15.1 Connected / Smart Drug Delivery Devices: List of Funding and Investments, since 2021
Table 17.1 FDA Centers for Drug and Device Approval
Table 17.2 Regulatory Review Timelines for Combination Products in the US
Table 17.3 Regulatory Bodies in EU5 Countries
Table 17.4 SFDA: Regulatory Review Timeline
Table 27.1 Connected Drug Delivery Devices Market: Leading Industry Players
Table 27.1 Company A: Company Overview
Table 27.2 Company B: Company Overview
Table 27.3 Company C: Company Overview
Table 27.4 Company D: Company Overview
Table 27.5 Company E: Company Overview
Table 27.6 Company F: Company Overview
Table 27.7 Company G: Company Overview
Table 27.8 Company H: Company Overview
Table 27.9 Company I: Company Overview
Table 27.10 Company J: Company Overview
Table 27.11 Company K: Company Overview
Table 28.1 Connected / Smart Drug Delivery Devices: Distribution by Stage of Development
Table 28.2 Connected / Smart Drug Delivery Devices: Distribution by Launch Year
Table 28.3 Connected / Smart Drug Delivery Devices: Distribution by Type of Integrated Device
Table 28.4 Connected / Smart Drug Delivery Devices: Distribution by Route of Administration
Table 28.5 Connected / Smart Drug Delivery Devices: Distribution by Therapeutic Area
Table 28.6 Connected / Smart Drug Delivery Devices: Distribution by Target Indication
Table 28.7 Connected / Smart Drug Delivery Devices: Distribution by Key Features
Table 28.8 Connected / Smart Drug Delivery Devices: Distribution by Mode of Connectivity
Table 28.9 Connected / Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
Table 28.10 Connected / Smart Drug Delivery Devices: Distribution by Availability of Data Storage / Cloud Platform
Table 28.11 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Year of Establishment
Table 28.12 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Company Size
Table 28.13 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Location of Headquarters
Table 28.14 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Year of Establishment and Location of Headquarters (Region)
Table 28.15 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Company Size and Location of Headquarters (Region)
Table 28.16 Most Active Players: Distribution by Number of Connected / Smart Drug Delivery Devices Manufactured
Table 28.17 Add-on Sensors: Distribution by Stage of Development
Table 28.18 Add-on Sensors: Distribution by Launch Year
Table 28.19 Add-on Sensors: Distribution by Compatible Device
Table 28.20 Add-on Sensors: Distribution by Route of Administration
Table 28.21 Add-on Sensors: Distribution by Target Indication
Table 28.22 Add-on Sensors: Distribution by Therapeutic Area
Table 28.23 Add-on Sensors: Distribution by Key Features
Table 28.24 Add-on Sensors: Distribution by Mode of Connectivity
Table 28.25 Add-on Sensors: Distribution by Availability of Companion Mobile Application
Table 28.26 Add-on Sensors: Distribution by Availability of Data Storage / Cloud Platform
Table 28.27 Add-on Sensor Manufacturers: Distribution by Year of Establishment
Table 28.28 Add-on Sensor Manufacturers: Distribution by Company Size
Table 28.29 Add-on Sensor Manufacturers: Distribution by Location of Headquarters
Table 28.30 Add-on Sensor Manufacturers: Distribution by Year of Establishment and Location of Headquarters
Table 28.31 Add-on Sensor Manufacturers: Distribution by Company Size and Location of Headquarters
Table 28.32 Most Active Players: Distribution by Number of Add-on Sensors Manufactured
Table 28.33 Medtronic: Business Segment-wise Revenues and Consolidated Financial Details (USD Billion)
Table 28.34 Insulet: Business Segment-wise Revenues and Consolidated Financial Details (USD Million)
Table 28.35 Tandem Diabetes Care: Consolidated Financial Details (USD Million)
Table 28.36 Gerresheimer: Business Segment-wise Revenues and Consolidated Financial Details (EUR Million)
Table 28.37 Roche: Business Segment-wise Revenues and Consolidated Financial Details (CHF Billion)
Table 28.38 Ypsomed: Business Segment-wise Revenues and Consolidated Financial Details (CHF Million)
Table 28.39 Clinical Trial Analysis: Distribution by Trial Registration Year, since 2021
Table 28.40 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, since 2021
Table 28.41 Clinical Trial Analysis: Distribution by Trial Status
Table 28.42 Clinical Trial Analysis: Distribution by Enrolled Patient Population by Trial Registration Year
Table 28.43 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 28.44 Clinical Trial Analysis: Distribution of Number of Enrolled Patient Population by Trial Status
Table 28.45 Clinical Trial Analysis: Distribution by Target Patient Population
Table 28.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 28.47 Clinical Trial Analysis: Distribution by Study Design
Table 28.48 Clinical Trial Analysis: Distribution by Type of Allocation
Table 28.49 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 28.50 Clinical Trial Analysis: Distribution by Type of Masking
Table 28.51 Clinical Trial Analysis: Distribution by Trial Purpose
Table 28.52 Leading Players: Distribution by Number of Registered Trials
Table 28.53 Leading Connected / Smart Drug Delivery Devices and Add-On Sensors: Distribution by Number of Registered Trials
Table 28.54 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 28.55 Clinical Trial Analysis: Distribution of Number of Registered Trials by Trial Status and Geography
Table 28.56 Clinical Trial Analysis: Distribution of Number of Enrolled Patients Population by Geography
Table 28.57 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2021
Table 28.58 Partnerships and Collaborations: Distribution by Type of Partnership
Table 28.59 Partnerships and Collaborations: Distribution by Year and Type of Partnership, since 2021
Table 28.60 Partnerships and Collaborations: Distribution by Class of Device
Table 28.61 Partnerships and Collaborations: Distribution by Type of Integrated Device
Table 28.62 Partnerships and Collaborations: Distribution by Compatible Device
Table 28.63 Most Active Players: Distribution by Number of Partnerships
Table 28.64 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 28.65 Partnerships and Collaborations: Local and International Deals
Table 28.66 Funding and Investment Analysis: Cumulative Year-wise Trend, since 2021
Table 28.67 Funding and Investment Analysis: Distribution by Amount Invested, since 2021 (USD Million)
Table 28.68 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Table 28.69 Funding and Investments: Distribution by Amount Invested by Type of Funding (USD Million)
Table 28.70 Distribution of Funding Instances by Year and Type of Funding, since 2021
Table 28.71 Funding and Investments: Distribution of Funding Instances by Geography
Table 28.72 Most Active Players: Distribution by Number of Funding Instances
Table 28.73 Most Active Players: Distribution by Amount Raised (USD Million)
Table 28.74 Funding and Investments Summary, since 2021 (USD Million)
Table 28.75 Global Connected Drug Delivery Devices Demand, Historical Trends, since 2020 (Million Units Sold)
Table 28.76 Global Connected Drug Delivery Devices Demand, till 2035 (Million Units Sold)
Table 28.77 Global Connected Drug Delivery Devices Market, Historical Trends, Since 2020 (USD Million)
Table 28.78 Global Connected Drug Delivery Devices Market, till 2035 (USD Million)
Table 28.79 Connected Drug Delivery Devices Market: Distribution by Type of Device (USD Million)
Table 28.80 Connected Drug Delivery Devices Demand for Connected / Smart Wearable Injectors, Historical Trends, since 2020 (Million Units Sold)
Table 28.81 Connected Drug Delivery Devices Demand for Connected / Smart Wearable Injectors, till 2035 (Million Units Sold)
Table 28.82 Connected Drug Delivery Devices Market for Connected / Smart Wearable Injectors, Historical Trends, Since 2020 (USD Million)
Table 28.83 Connected Drug Delivery Devices Market for Connected / Smart Wearable Injectors, till 2035 (USD Million)
Table 28.84 Connected Drug Delivery Devices Demand for Connected / Smart Inhalers, Historical Trends, since 2020 (Million Units Sold)
Table 28.85 Connected Drug Delivery Devices Demand for Connected / Smart Inhalers, till 2035 (Million Units Sold)
Table 28.86 Connected Drug Delivery Devices Market for Connected / Smart Inhalers, Historical Trends, since 2020 (USD Million)
Table 28.87 Connected Drug Delivery Devices Market for Connected / Smart Inhalers, till 2035 (USD Million)
Table 28.88 Connected Drug Delivery Devices Demand for Connected / Smart Pen Injectors, Historical Trends, since 2020 (Million Units Sold)
Table 28.89 Connected Drug Delivery Devices Demand for Connected / Smart Pen Injectors, till 2035 (Million Units Sold)
Table 28.90 Connected Drug Delivery Devices Market for Connected / Smart Pen Injectors, Historical Trends, since 2020 (USD Million)
Table 28.91 Connected Drug Delivery Devices Market for Connected / Smart Pen Injectors, till 2035 (USD Million)
Table 28.92 Connected Drug Delivery Devices Demand for Connected / Smart Autoinjectors, Historical Trends, since 2020 (Million Units Sold)
Table 28.93 Connected Drug Delivery Devices Demand for Connected / Smart Autoinjectors, till 2035 (Million Units Sold)
Table 28.94 Connected Drug Delivery Devices Market for Connected / Smart Autoinjectors, Historical Trends, since 2020 (USD Million)
Table 28.95 Connected Drug Delivery Devices Market for Connected / Smart Autoinjectors, till 2035 (USD Million)
Table 28.96 Connected Drug Delivery Devices Demand for Connected / Smart Needle-free Injection Systems, till 2035 (Million Units Sold)
Table 28.97 Connected Drug Delivery Devices Demand for Connected / Smart Needle-free Injection Systems, till 2035 (USD Million)
Table 28.98 Connected Drug Delivery Devices Market: Distribution by Mode of Connectivity, 2020, 2024 and 2035 (USD Million)
Table 28.99 Connected Drug Delivery Devices Demand for Bluetooth-enabled Devices, Historical Trends, since 2020 (Million Units Sold)
Table 28.100 Connected Drug Delivery Devices Demand for Bluetooth-enabled Devices, till 2035 (Million Units Sold)
Table 28.101 Connected Drug Delivery Devices Market for Bluetooth-enabled Devices, Historical Trends, since 2020 (USD Million)
Table 28.102 Connected Drug Delivery Devices Market for Bluetooth-enabled Devices, till 2035 (USD Million)
Table 28.103 Connected Drug Delivery Devices Demand for Near-field Communication-enabled Devices, Historical Trends, since 2020 (Million Units Sold)
Table 28.104 Connected Drug Delivery Devices Demand for Near-field Communication-enabled Devices, till 2035 (Million Units Sold)
Table 28.105 Connected Drug Delivery Devices Market for Near-field Communication-enabled Devices, Historical Trends, since 2020 (USD Million)
Table 28.106 Connected Drug Delivery Devices Market for Near-field Communication-enabled Devices, till 2035 (USD Million)
Table 28.107 Connected Drug Delivery Devices Demand for Cellular-enabled Devices, Historical Trends, since 2020 (Million Units Sold)
Table 28.108 Connected Drug Delivery Devices Demand for Cellular-enabled Devices, till 2035 (Million Units Sold)
Table 28.109 Connected Drug Delivery Devices Market for Cellular-enabled Devices, Historical Trends, since 2020 (USD Million)
Table 28.110 Connected Drug Delivery Devices Market for Cellular-enabled Devices, till 2035 (USD Million)
Table 28.111 Connected Drug Delivery Devices Demand for Wide Area Network-enabled Devices, Historical Trends, since 2020 (Million Units Sold)
Table 28.112 Connected Drug Delivery Devices Demand for Wide Area Network-enabled Devices, till 2035 (Million Units Sold)
Table 28.113 Connected Drug Delivery Devices Market for Wide Area Network-enabled Devices, Historical Trends, since 2020 (USD Million)
Table 28.114 Connected Drug Delivery Devices Market for Wide Area Network-enabled Devices, till 2035 (USD Million)
Table 28.115 Connected Drug Delivery Devices Market: Distribution by Route of Administration, 2020, 2024 and 2035 (USD Million)
Table 28.116 Connected Drug Delivery Demand for Parenteral Administration, Historical Trends, since 2020 (Million Units Sold)
Table 28.117 Connected Drug Delivery Devices Demand for Parenteral Administration, till 2035 (Million Units Sold)
Table 28.118 Connected Drug Delivery Devices Market for Parenteral Administration, Historical Trends, since 2020 (USD Million)
Table 28.119 Connected Drug Delivery Devices Market for Parenteral Administration, till 2035 (USD Million)
Table 28.120 Connected Drug Delivery Devices Demand for Inhalational Administration, Historical Trends, since 2020 (Million Units Sold)
Table 28.121 Connected Drug Delivery Devices Demand for Inhalational Administration, till 2035 (Million Units Sold)
Table 28.122 Connected Drug Delivery Devices Market for Inhalational Administration, Since 2020 (USD Million)
Table 28.123 Connected Drug Delivery Devices Market for Inhalational Administration, till 2035 (USD Million)
Table 28.124 Connected Drug Delivery Devices Market: Distribution by Therapeutic Area, 2020, 2024 and 2035 (USD Million)
Table 28.125 Connected Drug Delivery Devices Demand for Metabolic Disorders, Historical Trends, since 2020 (Million Units Sold)
Table 28.126 Connected Drug Delivery Devices Demand for Metabolic Disorders, till 2035 (Million Units Sold)
Table 28.127 Connected Drug Delivery Devices Market for Metabolic Disorders, Historical Trends, since 2020 (USD Million)
Table 28.128 Connected Drug Delivery Devices Market for Metabolic Disorders, till 2035 (USD Million)
Table 28.129 Connected Drug Delivery Devices Demand for Respiratory Disorders, Historical Trends, since 2020 (Million Units Sold)
Table 28.130 Connected Drug Delivery Devices Demand for Respiratory Disorders, till 2035 (Million Units Sold)
Table 28.131 Connected Drug Delivery Devices Market for Respiratory Disorders, Historical Trends, since 2020 (USD Million)
Table 28.132 Connected Drug Delivery Devices Market for Respiratory Disorders, till 2035 (USD Million)
Table 28.133 Connected Drug Delivery Devices Demand for Autoimmune Disorders, Historical Trends, since 2020 (Million Units Sold)
Table 28.134 Connected Drug Delivery Devices Demand for Autoimmune Disorders, till 2035 (Million Units Sold)
Table 28.135 Connected Drug Delivery Devices Market for Autoimmune Disorders, Historical Trends, since 2020 (USD Million)
Table 28.136 Connected Drug Delivery Devices Market for Autoimmune Disorders, till 2035 (USD Million)
Table 28.137 Connected Drug Delivery Devices Demand for Other Disorders, Historical Trends, since 2020 (Million Units Sold)
Table 28.138 Connected Drug Delivery Devices Demand for Other Disorders, till 2035 (Million Units Sold)
Table 28.139 Connected Drug Delivery Devices Market for Other Disorders, Historical Trends, since 2020 (USD Million)
Table 28.140 Connected Drug Delivery Devices Market for Other Disorders, till 2035 (USD Million)
Table 28.141 Connected Drug Delivery Devices Market: Distribution by Geographical Regions, 2020, 2024 and 2035 (USD Million)
Table 28.142 Connected Drug Delivery Devices Demand in North America, Historical Trends, since 2020 (Million Units Sold)
Table 28.143 Connected Drug Delivery Devices Demand in North America, till 2035 (Million Units Sold)
Table 28.144 Connected Drug Delivery Devices Market in North America, Historical Trends, since 2020 (USD Million)
Table 28.145 Connected Drug Delivery Devices Market in North America, till 2035 (USD Million)
Table 28.146 Connected Drug Delivery Devices Market in the US, Historical Trends, Since 2020 (USD Million)
Table 28.147 Connected Drug Delivery Devices Market in the US, till 2035 (USD Million)
Table 28.148 Connected Drug Delivery Devices Market in Canada, Historical Trends, since 2020 (USD Million)
Table 28.149 Connected Drug Delivery Devices Market in Canada, till 2035 (USD Million)
Table 28.150 Connected Drug Delivery Devices Demand in Europe, Historical Trends, since 2020 (Million Units Sold)
Table 28.151 Connected Drug Delivery Devices Demand in Europe, till 2035 (Million Units Sold)
Table 28.152 Connected Drug Delivery Devices Market in Europe, Historical Trends, since 2020 (USD Million)
Table 28.153 Connected Drug Delivery Devices Market in Europe, till 2035 (USD Million)
Table 28.154 Connected Drug Delivery Devices Market in the UK, Historical Trends, since 2020 (USD Million)
Table 28.155 Connected Drug Delivery Devices Market in the UK, till 2035 (USD Million)
Table 28.156 Connected Drug Delivery Devices Market in Germany, Historical Trends, since 2020 (USD Million)
Table 28.157 Connected Drug Delivery Devices Market in Germany, till 2035 (USD Million)
Table 28.158 Connected Drug Delivery Devices Market in France, Historical Trends, Since 2020 (USD Million)
Table 28.159 Connected Drug Delivery Devices Market in France, till 2035 (USD Million)
Table 28.160 Connected Drug Delivery Devices Market in Italy, Historical Trends, since 2020 (USD Million)
Table 28.161 Connected Drug Delivery Devices Market in Italy, till 2035 (USD Million)
Table 28.162 Connected Drug Delivery Devices Market in Spain, Historical Trends, since 2020 (USD Million)
Table 28.163 Connected Drug Delivery Devices Market in Spain, till 2035 (USD Million)
Table 28.164 Connected Drug Delivery Devices Market in Rest of Europe, Historical Trends, since 2020 (USD Million)
Table 28.165 Connected Drug Delivery Devices Market in Rest of Europe, till 2035 (USD Million)
Table 28.166 Connected Drug Delivery Devices Demand in Asia-Pacific, Historical Trends, since 2020 (Million Units Sold)
Table 28.167 Connected Drug Delivery Devices Demand in Asia-Pacific, till 2035 (Million Units Sold)
Table 28.168 Connected Drug Delivery Devices Market in Asia-Pacific, Historical Trends, since 2020 (USD Million)
Table 28.169 Connected Drug Delivery Devices Market in Asia-Pacific, till 2035 (USD Million)
Table 28.170 Connected Drug Delivery Devices Market in China, Historical Trends, since 2020 (USD Million)
Table 28.171 Connected Drug Delivery Devices Market in China, till 2035 (USD Million)
Table 28.172 Connected Drug Delivery Devices Market in India, Historical Trends, Since 2020 (USD Million)
Table 28.173 Connected Drug Delivery Devices Market in India, till 2035 (USD Million)
Table 28.174 Connected Drug Delivery Devices Market in Japan, Historical Trends, Since 2020 (USD Million)
Table 28.175 Connected Drug Delivery Devices Market in Japan, till 2035 (USD Million)
Table 28.176 Connected Drug Delivery Devices Market in Rest of the Asia-Pacific, Historical Trends, since 2020 (USD Million)
Table 28.177 Connected Drug Delivery Devices Market in Rest of the Asia-Pacific, till 2035 (USD Million)
Table 28.178 Connected Drug Delivery Devices Demand in Middle East and North Africa, Historical Trends, since 2020 (Million Units Sold)
Table 28.179 Connected Drug Delivery Devices Demand in Middle East and North Africa, till 2035 (Million Units Sold)
Table 28.180 Connected Drug Delivery Devices Market in Middle East and North Africa, Historical Trends, Since 2020 (USD Million)
Table 28.181 Connected Drug Delivery Devices Market in Middle East and North Africa, till 2035 (USD Million)
Table 28.182 Connected Drug Delivery Devices Market in Egypt, Historical Trends, since 2020 (USD Million)
Table 28.183 Connected Drug Delivery Devices Market in Egypt, till 2035 (USD Million)
Table 28.184 Connected Drug Delivery Devices Market in Israel, Historical Trends, since 2020 (USD Million)
Table 28.185 Connected Drug Delivery Devices Market in Israel, till 2035 (USD Million)
Table 28.186 Connected Drug Delivery Devices Market in Saudi Arabia, Historical Trends, since 2020 (USD Million)
Table 28.187 Connected Drug Delivery Devices Market in Saudi Arabia, till 2035 (USD Million)
Table 28.188 Connected Drug Delivery Devices Market in Rest of the Middle East and North Africa, Historical Trends, since 2020 (USD Million)
Table 28.189 Connected Drug Delivery Devices Market in Rest of the Middle East and North Africa, till 2035 (USD Million)
Table 28.190 Connected Drug Delivery Devices Demand in Latin America and Rest of the World, Historical Trends, since 2020 (Million Units Sold)
Table 28.191 Connected Drug Delivery Devices Demand in Latin America and Rest of the World, till 2035 (Million Units Sold)
Table 28.192 Connected Drug Delivery Devices Market in Latin America and Rest of the World, Historical Trends, since 2020 (USD Million)
Table 28.193 Connected Drug Delivery Devices Market in Latin America and Rest of the World, till 2035 (USD Million)
Table 28.194 Connected Drug Delivery Devices Market in Brazil, Historical Trends, since 2020 (USD Million)
Table 28.195 Connected Drug Delivery Devices Market in Brazil, till 2035 (USD Million)
Table 28.196 Connected Drug Delivery Devices Market in Argentina, Historical Trends, since 2020 (USD Million)
Table 28.197 Connected Drug Delivery Devices Market in Argentina, till 2035 (USD Million)
Table 28.198 Connected Drug Delivery Devices Market in Rest of the World, Historical Trends, since 2020 (USD Million)
Table 28.199 Connected Drug Delivery Devices Market in Rest of the World, till 2035 (USD Million)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Key Market Segmentation
Figure 3.3 Market Dynamics: Robust Quality Control
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Connected / Smart Drug Delivery Devices Market Landscape
Figure 5.2 Executive Summary: Add-on Sensors Market Landscape
Figure 5.3 Executive Summary: Market Trends
Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Different Components of IoT Ecosystem
Figure 6.2 Framework of Connected / Smart Drug Delivery Devices
Figure 6.3 Key Considerations for Designing and Developing a Connected / Smart Drug Delivery Device
Figure 6.4 Stack Model for the Development of Connected Drug Delivery Devices
Figure 6.5 Type of Technology Used for Connected / Smart Drug Delivery Device
Figure 6.6 Advantages of Connected / Smart Drug Delivery Devices
Figure 7.1 Connected / Smart Drug Delivery Devices: Distribution by Stage of Development
Figure 7.2 Connected / Smart Drug Delivery Devices: Distribution by Launch Year
Figure 7.3 Connected / Smart Drug Delivery Devices: Distribution by Type of Integrated Device
Figure 7.4 Connected / Smart Drug Delivery Devices: Distribution by Route of Administration
Figure 7.5 Connected / Smart Drug Delivery Devices: Distribution by Target Indication
Figure 7.6 Connected / Smart Drug Delivery Devices: Distribution by Therapeutic Area
Figure 7.7 Connected / Smart Drug Delivery Devices: Distribution by Key Features
Figure 7.8 Connected / Smart Drug Delivery Devices: Distribution by Mode of Connectivity
Figure 7.9 Connected / Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
Figure 7.10 Connected / Smart Drug Delivery Devices: Distribution by Availability of Data Storage / Cloud Platform
Figure 7.11 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Year of Establishment
Figure 7.12 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Company Size
Figure 7.13 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Location of Headquarters
Figure 7.14 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Year of Establishment and Location of Headquarters
Figure 7.15 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Company Size and Location of Headquarters
Figure 7.16 Most Active Players: Distribution by Number of Connected / Smart Drug Delivery Devices Manufactured
Figure 8.1 Add-on Sensors: Distribution by Stage of Development
Figure 8.2 Add-on Sensors: Distribution by Launch Year
Figure 8.3 Add-on Sensors: Distribution by Compatible Device
Figure 8.4 Add-on Sensors: Distribution by Route of Administration
Figure 8.5 Add-on Sensors: Distribution by Target Indication
Figure 8.6 Add-on Sensors: Distribution by Therapeutic Area
Figure 8.7 Add-on Sensors: Distribution by Key Features
Figure 8.8 Add-on Sensors: Distribution by Mode of Connectivity
Figure 8.9 Add-on Sensors: Distribution by Availability of Companion Mobile Application
Figure 8.10 Add-on Sensors: Distribution by Availability of Data Storage / Cloud Platform
Figure 8.11 Add-on Sensor Manufacturers: Distribution by Year of Establishment
Figure 8.12 Add-on Sensor Manufacturers: Distribution by Company Size
Figure 8.13 Add-on Sensor Manufacturers: Distribution by Location of Headquarters
Figure 8.14 Add-on Sensor Manufacturers: Distribution by Year of Establishment and Location of Headquarters
Figure 8.15 Add-on Sensor Manufacturers: Distribution by Company Size and Location of Headquarters
Figure 8.16 Most Active Players: Distribution by Number of Add-on Sensors Manufactured
Figure 9.1 Product Competitiveness Analysis: Smart Handheld Injectors (Peer Group 1a)
Figure 9.2 Product Competitiveness Analysis: Smart Wearable Injectors (Peer Group 1b)
Figure 9.3 Product Competitiveness Analysis: Other Integrated Devices (Peer Group 1c)
Figure 9.4 Product Competitiveness Analysis: Add-on Sensors (Peer Group 2)
Figure 10.1 Medtronic: Business Segment-wise Revenues and Consolidated Financial Details (USD Billion)
Figure 10.2 Insulet: Business Segment-wise Revenues and Consolidated Financial Details (USD Millon)
Figure 10.3 Tandem Diabetes Care: Consolidated Financial Details (USD Million)
Figure 11.1 Gerresheimer: Business Segment-wise Revenues and Consolidated Financial Details (EUR Million)
Figure 11.2 Roche: Business Segment-wise Revenues and Consolidated Financial Details (CHF Billion)
Figure 11.3 Ypsomed: Business Segment-wise Revenues and Consolidated Financial Details (CHF Million)
Figure 13.1 Clinical Trial Analysis: Cumulative Year-wise Trend, since 2021
Figure 13.2 Clinical Trial Analysis: Year-wise Trend of Enrolled Patient Population by Trial Registration Year, since 2021
Figure 13.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 13.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 13.5 Clinical Trial Analysis: Distribution of Number of Enrolled Patient Population by Trial Status
Figure 13.6 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 13.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 13.8 Clinical Trial Analysis: Distribution by Study Design
Figure 13.9 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 13.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 13.11 Clinical Trial Analysis: Distribution by Type of Masking
Figure 13.12 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 13.13 Leading Players: Distribution by Number of Registered Trials
Figure 13.14 Leading Connected / Smart Drug Delivery Devices and Add-On Sensors: Distribution by Number of Registered Trials
Figure 13.15 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 13.16 Clinical Trial Analysis: Distribution of Number of Registered Trials by Trial Status and Geography
Figure 13.17 Clinical Trial Analysis: Distribution of Number of Enrolled Patients Population by Geography
Figure 14.1 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2021
Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, since 2021
Figure 14.4 Partnerships and Collaborations: Distribution by Class of Device
Figure 14.5 Partnerships and Collaborations: Distribution by Type of Integrated Device
Figure 14.6 Partnerships and Collaborations: Distribution by Compatible Device
Figure 14.7 Most Active Players: Distribution by Number of Partnerships
Figure 14.8 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 14.9 Partnerships and Collaborations: Local and International Deals
Figure 15.1 Funding and Investments: Cumulative Year-wise Trend, since 2021
Figure 15.2 Funding and Investments: Distribution by Amount Invested, since 2021 (USD Million)
Figure 15.3 Funding and Investments: Distribution of Funding Instances by Type of Funding
Figure 15.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 15.5 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding, since 2021
Figure 15.6 Funding and Investments: Distribution of Funding Instances by Geography
Figure 15.7 Most Active Players: Distribution by Number of Funding Instances
Figure 15.8 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 15.9 Summary of Funding and Investments, since 2021 (USD Million)
Figure 16.1 Connected / Smart Drug Delivery Devices: Value Chain
Figure 16.2 Cost Distribution Across Value Chain
Figure 16.3 Costs Associated with Concept Development and Proof of Concept
Figure 16.4 Costs Associated with Research and Product Development
Figure 16.5 Costs Associated with Clinical Trials
Figure 16.6 Costs Associated with Regulatory Approvals
Figure 16.7 Costs Associated with Manufacturing and Product Assembly
Figure 16.8 Costs Associated with Application Development
Figure 16.9 Costs Associated with Marketing and Sales
Figure 17.1 Global Regulations related to Smart Inhalers, Smart Injectors and Smart Wearable Injectors
Figure 17.2 USFDA: Approval Pathway for Combination Products
Figure 17.3 Health Canada: Approval Pathway for Combination Products
Figure 17.4 NMPA: Approval Pathway for Combination Products
Figure 17.5 Connected / Smart Drug Delivery Devices: Major Steps for Managing Privacy
Figure 18.1 Diabetes: Evolution of Drug Delivery / Connected Devices
Figure 18.2 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Diabetic Patients: Highlights on Twitter
Figure 18.3 Asthma: Evolution of Drug Delivery / Connected Devices
Figure 18.4 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Asthmatic Patients: Highlights on Twitter
Figure 19.1 Connected Drug Delivery Devices Market: SWOT Analysis
Figure 19.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 20.1 Blue Ocean Strategy: Strategy Canvas
Figure 20.2 Blue Ocean Strategy: Pioneer-Migrator (PMS) Map
Figure 21.1 Global Connected Drug Delivery Devices Market: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 21.2 Global Connected Drug Delivery Devices Market, till 2035: Conservative Scenario (Million Units Sold, USD Million)
Figure 21.3 Global Connected Drug Delivery Devices Market, till 2035: Optimistic Scenario (Million Units Sold, USD Million)
Figure 22.1 Connected Drug Delivery Devices Market: Distribution by Type of Device (USD Million)
Figure 22.2 Connected Drug Delivery Devices Market for Connected / Smart Wearable Injectors: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 22.3 Connected Drug Delivery Devices Market for Connected / Smart Inhalers: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 22.4 Connected Drug Delivery Devices Market for Connected / Smart Pen Injectors: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 22.5 Connected Drug Delivery Devices Market for Connected / Smart Autoinjectors: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million, Million Units Sold)
Figure 22.6 Connected Drug Delivery Devices Market for Connected / Smart Needle-free Injection Systems: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million, Million Units Sold)
Figure 23.1 Connected Drug Delivery Devices Market: Distribution by Mode of Connectivity (USD Million)
Figure 23.2 Connected Drug Delivery Devices Market for Bluetooth-enabled Devices: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 23.3 Connected Drug Delivery Devices Market for Near-field Communication-enabled Devices: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 23.4 Connected Drug Delivery Devices Market for Cellular-enabled Devices: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 23.5 Connected Drug Delivery Devices Market for Wide Area Network-enabled Devices: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 24.1 Connected Drug Delivery Devices Market: Distribution by Route of Administration (USD Million)
Figure 24.2 Connected Drug Delivery Devices Market for Parenteral Administration: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 24.3 Connected Drug Delivery Devices Market for Inhalational Administration: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 25.1 Connected Drug Delivery Devices Market: Distribution by Therapeutic Area (USD Million)
Figure 25.2 Connected Drug Delivery Devices Market for Metabolic Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 25.3 Connected Drug Delivery Devices Market for Respiratory Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 25.4 Connected Drug Delivery Devices Market for Autoimmune Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 25.5 Connected Drug Delivery Devices Market for Other Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 26.1 Connected Drug Delivery Devices Market: Distribution by Geographical Regions (USD Million)
Figure 26.2 Connected Drug Delivery Devices Market in North America: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 26.3 Connected Drug Delivery Devices Market in the US: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.4 Connected Drug Delivery Devices Market in Canada: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.5 Connected Drug Delivery Devices Market in Europe: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 26.6 Connected Drug Delivery Devices Market in the UK: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.7 Connected Drug Delivery Devices Market in Germany: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.8 Connected Drug Delivery Devices Market in France: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.9 Connected Drug Delivery Devices Market in Italy: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.10 Connected Drug Delivery Devices Market in Spain: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.11 Connected Drug Delivery Devices Market in Rest of Europe: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.12 Connected Drug Delivery Devices Market in Asia-Pacific: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 26.13 Connected Drug Delivery Devices Market in China: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.14 Connected Drug Delivery Devices Market in India: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.15 Connected Drug Delivery Devices Market in Japan: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.16 Connected Drug Delivery Devices Market in Rest of Asia-Pacific: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.17 Connected Drug Delivery Devices Market in Middle East and North Africa: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 26.18 Connected Drug Delivery Devices Market in Egypt: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.19 Connected Drug Delivery Devices Market in Israel: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.20 Connected Drug Delivery Devices Market in Saudi Arabia: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.21 Connected Drug Delivery Devices Market in Rest of Middle East and North Africa: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.22 Connected Drug Delivery Devices Market in Latin America and Rest of the World: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (Million Units Sold, USD Million)
Figure 26.23 Connected Drug Delivery Devices Market in Brazil: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.24 Connected Drug Delivery Devices Market in Argentina: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.25 Connected Drug Delivery Devices Market in Other Countries: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 27.1 Concluding Remarks: Connected Drug Delivery Devices Market Landscape
Figure 27.2 Concluding Remarks: Add-on-Sensors Market Landscape
Figure 27.3 Concluding Remarks: Partnerships and Collaborations
Figure 27.4 Concluding Remarks: Funding and Investments
Figure 27.5 Concluding Remarks: Market Sizing and Opportunity Analysis

02-2729-4219

+886-2-2729-4219

License/价格

互联药物传输设备市场（第三版）：依设备类型、连接方式、给药途径、治疗领域和地区划分 - 趋势与至2035年的预测

Connected Drug Delivery Devices Market (3rd Edition): Distribution by Type of Device, Mode of Connectivity, Route of Administration, Therapeutic Area & Geographical Regions - Trends and Forecast Till 2035

互联药物传输设备市场 - 概述

互联药物输送设备市场的主要参与者

目录

第1章 引言

第2章 研究方法

第3章 市场动态

第4章 宏观经济指标

第5章 执行摘要

第6章 引言

第7章 市场概况：互联/智慧型药物传输设备

第8章 市场概况：附加感知器

第9章 产品竞争分析

第10章 公司简介：北方美国互联/智慧药物传输设备製造商

第11章 公司简介：欧洲互联/智慧药物传输设备製造商

第12章 公司简介：亚太及其他地区互联/智慧药物传输设备製造商

第13章 临床试验分析

第14章 伙伴关係与合作

第15章 资金与投资分析

第16章 价值链分析

第17章 互联/智慧型药物输送装置的监管环境

第18章 案例研究：应用互联药物输送装置提高用药依从性

第19章 SWOT分析

第20章 蓝海策略

第21章 全球互联药物输送设备市场

第22章 互联药物输送设备市场（依设备类型划分）

第23章 互联药物输送设备市场（以连接方式划分）

第24章 互联药物输送设备市场（依给药途径划分）

第25章 互联药物输送设备市场（依治疗领域划分）

第26章 互联药物输送设备市场（依地区划分）

第27章 互联药物输送设备市场（依主要厂商划分）

第28 结论

第29章 高层洞察

第30章 附录1：表格资料

第31章 附录2：公司与组织清单

第32章 附录3：2015-2020年合作伙伴关係

Connected Drug Delivery Devices Market: Overview

Primary Research Overview

Example Players in Connected Drug Delivery Devices Market

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. MACRO-ECONOMIC INDICATORS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

7. MARKET LANDSCAPE: CONNECTED / SMART DRUG DELIVERY DEVICES

8. MARKET LANDSCAPE: ADD-ON SENSORS

9. PRODUCT COMPETITIVENESS ANALYSIS

10. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN NORTH AMERICA

11. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN EUROPE

12. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD

13. CLINICAL TRIAL ANALYSIS

14. PARTNERSHIPS AND COLLABORATIONS

15. FUNDING AND INVESTMENT ANALYSIS

16. VALUE CHAIN ANALYSIS

17. REGULATORY LANDSCAPE FOR CONNECTED / SMART DRUG DELIVERY DEVICES

18. CASE STUDIES: APPLICATION OF CONNECTED DRUG DELIVERY DEVICES TO IMPROVE MEDICATION ADHERENCE

19. SWOT ANALYSIS

20. BLUE OCEAN STRATEGY

21. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET

22. CONNECTED DRUG DELIVERY DEVICES MARKET, BY TYPE OF DEVICE

23. CONNECTED DRUG DELIVERY DEVICES MARKET, BY MODE OF CONNECTIVITY

24. CONNECTED DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION

25. CONNECTED DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC AREA

26. CONNECTED DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHICAL REGIONS

27. CONNECTED DRUG DELIVERY DEVICES MARKET, BY LEADING PLAYERS

28. CONCLUDING REMARKS

29. EXECUTIVE INSIGHTS

30. APPENDIX 1: TABULATED DATA

31. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

32. APPENDIX 3: PARTNERSHIPS AND COLLABORATIONS, 2015-2020

List of Tables

List of Figures

第1章引言

第2章研究方法

第3章市场动态

第4章宏观经济指标

第5章执行摘要

第6章引言

第7章市场概况：互联/智慧型药物传输设备

第8章市场概况：附加感知器

第9章产品竞争分析

第10章公司简介：北方美国互联/智慧药物传输设备製造商

第11章公司简介：欧洲互联/智慧药物传输设备製造商

第12章公司简介：亚太及其他地区互联/智慧药物传输设备製造商

第13章临床试验分析

第14章伙伴关係与合作

第15章资金与投资分析

第16章价值链分析

第17章互联/智慧型药物输送装置的监管环境

第18章案例研究：应用互联药物输送装置提高用药依从性

第20章蓝海策略

第21章全球互联药物输送设备市场

第22章互联药物输送设备市场（依设备类型划分）

第23章互联药物输送设备市场（以连接方式划分）

第24章互联药物输送设备市场（依给药途径划分）

第25章互联药物输送设备市场（依治疗领域划分）

第26章互联药物输送设备市场（依地区划分）

第27章互联药物输送设备市场（依主要厂商划分）

第29章高层洞察

第30章附录1：表格资料

第31章附录2：公司与组织清单

第32章附录3：2015-2020年合作伙伴关係